OBJECTIVES: We conducted a multicenter retrospective study to determine the results of treatment for @entity263 in solid organ transplant recipients. METHODS: A retrospective analysis of all @entity1 diagnosed with @entity263 after organ transplantation at five centers was conducted. Data were obtained by chart review and a multipoint data sheet was used to abstract the data from the @entity1 charts. RESULTS: Eighteen cases of @entity263 were identified from six institutions. Most (84%) of the @entity5 were clinically localized at the time of diagnosis. Nine (50%) of 18 @entity1 underwent radical prostatectomy, which was the predominant mode of treatment. Overall survival at a mean follow-up of 32 months was 66%, with a @entity5 specific mortality of 16%. Mortality was 13% for the 15 @entity1 with @entity66 and 33% for the 3 @entity1 with metastatic disease at the time of diagnosis. CONCLUSIONS: Most of the @entity1 with @entity263 being detected after solid organ transplantation were diagnosed with @entity66 . Aggressive therapeutic intervention as in the general (nontransplant) population yields good results and should be pursued. Diligent surveillance for @entity263 in this population using periodic digital rectal examination, serum @entity1486 , and prostate needle biopsy as needed will ensure earlier @entity5 detection and allow for definitive therapeutic intervention.

XXXX in the post-transplant population. Urologic Society for Transplantation and Vascular Surgery.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity66 :: ('MESH:D004194', 'Disease') :: ['localized disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity263 :: (MESH:D011471,Disease) :: ['Prostate cancer']
